. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial. npj Parkinson's Disease 3, Article number: 10 (2017 March 27)

Abstract:

Carolyn Peterson & R. Lee Mosley

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.